Litigation concerning Depo-Provera and meningioma centres on a specific allegation: that the manufacturer warned patients in some countries about a brain tumour risk while the United States label did not carry a comparable warning. This is a failure-to-warn case rather than a claim that the medication should never have existed.
This guide explains the basis of the claims, who may be eligible, what evidence is required, and how the process works. It describes active litigation in which no general outcome has been determined.
Key Takeaways
- The claims are consolidated in federal multidistrict litigation, which centralises pre-trial proceedings while individual cases remain separate.
- The central allegation is inadequate warning, supported by the difference between labelling in the United States and in other markets.
- Eligibility generally turns on prolonged use of the injection followed by a meningioma diagnosis.
- Prescription and pharmacy records establishing duration of use are the single most important evidence.
- No outcome has been determined, and bellwether results will shape how remaining claims are valued.
What the Litigation Alleges
Depo-Provera is an injectable contraceptive containing medroxyprogesterone acetate, administered every three months.
Research published in recent years reported an association between prolonged use of that compound and an increased risk of meningioma — a tumour arising from the membranes surrounding the brain and spinal cord. Meningiomas are usually non-cancerous, but their location means they can cause serious harm: headaches, vision loss, seizures, cognitive change, and in many cases a requirement for craniotomy with the risks that carries.
The legal claim is not that the association was unknowable. It is that regulators and patients in certain other jurisdictions received warnings about meningioma risk that were not reflected in comparable terms on the United States label — and that patients and prescribers here were therefore unable to weigh the risk or consider alternatives.
Defences raised in cases of this kind commonly include federal preemption arguments about labelling authority, disputes about the strength of the scientific association, and challenges to causation in the individual case.
How Multidistrict Litigation Works
Federal cases have been consolidated into multidistrict litigation before a single judge. This is worth understanding because it is frequently misdescribed.
Consolidation is not a class action. Each claim remains individual, with its own facts and its own value. What is centralised is pre-trial work — common discovery, expert challenges and scheduling — after which representative bellwether cases are tried to test how juries respond to the evidence.
Those bellwether outcomes then inform how the remaining claims are valued and whether any global resolution follows. That process takes years, and anyone told a settlement figure is already established should treat that as a warning sign about the source.
Checking Your Eligibility
Criteria are set by the specific facts of each case, but the recurring requirements are:
- Documented use of the injectable contraceptive, ideally over a prolonged period, since the reported association relates to extended exposure.
- A meningioma diagnosis, confirmed by imaging and, where surgery occurred, by pathology.
- A plausible temporal relationship between the period of use and the diagnosis.
- Records that establish both, which is where most enquiries succeed or fail.
Claims may also be available to the estate and family where someone has died from complications, following the wrongful death rules of the relevant state.
Deadlines vary by state and are commonly calculated from diagnosis, or from when the connection between the condition and the medication reasonably became apparent, rather than from the injections themselves. Because those periods differ substantially and some are short, eligibility should be checked promptly rather than assumed either way.
Gathering the Evidence
Documentation of exposure is the practical obstacle in most of these claims, because injections administered years ago at a clinic may not appear in current medical records.
- Pharmacy records, which are often the most complete source and can frequently be obtained directly from the dispensing pharmacy chain.
- Prescribing and administration records from every clinic or provider involved, including family planning services.
- Insurance claim histories, which independently establish dates of administration.
- Imaging — the actual scans, not just the radiology report, since they can be re-read.
- Operative and pathology reports where surgery took place.
- Neurology records documenting symptoms, treatment and any lasting deficit.
- Evidence of impact — time off work, reduced capacity, care required, and the cost of treatment.
Request records in writing and keep copies of the requests. Where a clinic has closed, records may have transferred to a successor or a state repository, which counsel can trace.
Filing the Claim
A complaint sets out the plaintiff’s use, the diagnosis, the alleged inadequacy of the warning, and the resulting harm. Where the case is filed into the consolidated proceedings, it joins the coordinated pre-trial process rather than proceeding independently through discovery.
Plaintiffs typically complete a detailed fact sheet covering medical history, use history, diagnosis and treatment. Accuracy matters — inconsistencies between the fact sheet and the medical records are used to challenge credibility later.
Expect the process to take years rather than months, and expect medical examination and deposition at some stage if the case advances.
Consulting a Lawyer
Pharmaceutical litigation is resource-intensive, requiring epidemiological and regulatory expertise alongside individual medical causation evidence. Ask any firm how many of these cases it is handling directly, whether it is filing cases itself or referring them elsewhere, and who will actually communicate with you.
Representation is normally on a contingency fee basis with no upfront cost and expenses advanced by the firm. Confirm the percentage, whether it changes at different stages, and whether it is calculated before or after expenses — in mass litigation, common benefit assessments may also be deducted, and that should be explained clearly at the outset.
Two cautions. Be sceptical of advertising promising specific figures, since no outcome has been determined. And do not stop or change any prescribed medication because of a legal claim — that is a decision for your clinician, and continuity of care matters both medically and evidentially.
What Compensation Might Cover
Where claims succeed, recoverable compensation in cases of this type typically includes past and future medical costs including surgery and monitoring, lost earnings and reduced earning capacity, and non-economic damages for pain, suffering and lasting impairment. Punitive damages may be sought where conduct is alleged to have been egregious, subject to state law.
Values in consolidated litigation are usually tiered by injury severity — the extent of surgery, whether deficits are permanent, and the effect on work and daily life.
Frequently Asked Questions
Is this a class action?
No. It is multidistrict litigation, where individual cases are consolidated for pre-trial purposes but retain their own facts and value. There is no single class recovery.
How long must I have used it?
The reported association relates to prolonged use, so duration is central. Exact criteria vary between firms and cases, which is why documentation of the injection history matters so much.
I cannot find my old records. Is that fatal?
Not necessarily. Pharmacy chains and insurers frequently hold histories going back years, and closed clinics often transfer records. Counsel can pursue these routes.
Are meningiomas cancerous?
Most are non-cancerous, but their location can cause serious symptoms and they frequently require surgery or ongoing monitoring. Severity is assessed on effect rather than on the benign classification.
How long will it take?
Years rather than months. Consolidated pharmaceutical litigation moves through common discovery and bellwether trials before individual resolution becomes realistic.
Should I stop the medication?
That is a medical decision for your clinician, not a legal one. Discuss any concerns with your prescriber rather than stopping unilaterally.
Key Takeaways
These claims rest on an alleged labelling failure rather than on the drug’s existence, and they turn on documented duration of use alongside a confirmed diagnosis. Gather the pharmacy and prescribing records first, check the deadline for your state promptly, and treat any promise of a specific figure with scepticism while the litigation remains unresolved. Firms handling risk of brain tumors associated with Depo-Provera should be able to explain the current procedural position clearly.
This article is general information about ongoing litigation, not legal or medical advice, and the position continues to develop. Consult a qualified attorney about eligibility and your clinician about any medication decision.
Related reading: Why Should You Hire a Birth Injury Lawyer.
Explore more in Legal Advice.
